HCW Biologics (HCWB)

• Market cap: $7.38M
• 1 day: -8.04%
• 5 days: -3.74%
• 1 month: -60.69%
• 3 months: 176.07%
• 6 months: -27.46%
• Year to date: -8.04%
• 1 year: -75.59%
• 5 years: -99.59%
• 10 years: -99.59%
• Sector: Healthcare
• Industry: Biotechnology

About: HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Employees: 35